Vacis, founded in 2016, is a pioneering force in the field of tissue engineering, focusing on the creation of body-own blood vessels specifically tailored for vascular surgeries. Their mission, articulated in their slogan, is to "Pioneer the future of vascular surgery with patient-specific blood vessels engineered for enduring performance and minimal complications."
Specializing in Biotechnology and Health Care, Vacis aims to significantly reduce the complications associated with prosthetic vascular grafts in surgeries. By providing autologous graft vessels, the company addresses the prevalent issue of graft failure, which leads to reduced patient morbidity and healthcare costs.
Their innovative approach has secured past investment, with their latest being a Venture Round on 11 October 2019 from notable investors like NV Industriebank LIOF, Brightlands Venture Partners, and HTGF | High-Tech Gruenderfonds. This backing highlights confidence in Vacis's potential to reshape vascular surgery treatments.
